RESULTS: In total, 5599 patients were included. MDR-TB accounted for 4.4% (216/4297) among new cases and 24.1% (162/672) among previously treated cases. From 2010 to 2014, proportion of MDR-TB had been gradually decreased among both new and previously treated cases (p<0.001 and p=0.027 for trend, respectively). In 378 patients with MDR-TB, resistance rate of ethambutol and pyrazinamide were high (63.8% and 35.7%, respectively). Resistance rate of any fuloroquinolone and second line injectable drugs were 13.8% and 6.9%, respectively. Resistance rates of group 4 drugs were as follows: para-aminosalicylic acid (31.5%), prothionamide (17.5%) and cycloserine (7.1%). Extensively drug-resistant tuberculosis (XDR TB) (12.4%, n=47) and pre-XDR TB (20.6%, n=78) accounted for 33.0% of MDR-TB.